Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J, Aragon-Ching JB, Wang J, Huang B, Laliberte RJ, di Pietro A, Grivas P. Powles T, et al. Among authors: ullen a. J Clin Oncol. 2023 Jul 1;41(19):3486-3492. doi: 10.1200/JCO.22.01792. Epub 2023 Apr 18. J Clin Oncol. 2023. PMID: 37071838 Free PMC article. Clinical Trial.
Idiotypic-anti-idiotypic complexes and their in vivo metabolism.
Johansson A, Erlandsson A, Eriksson D, Ullén A, Holm P, Sundström BE, Roux KH, Stigbrand T. Johansson A, et al. Among authors: ullen a. Cancer. 2002 Feb 15;94(4 Suppl):1306-13. doi: 10.1002/cncr.10301. Cancer. 2002. PMID: 11877761 Free article.
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullén A, Yachnin J, Nilsson S, Panaretakis T. Kharaziha P, et al. Among authors: ullen a. Oncotarget. 2015 Aug 28;6(25):21740-54. doi: 10.18632/oncotarget.3226. Oncotarget. 2015. PMID: 25844599 Free PMC article. Clinical Trial.
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.
Berglund Å, Ullén A, Lisyanskaya A, Orlov S, Hagberg H, Tholander B, Lewensohn R, Nygren P, Spira J, Harmenberg J, Jerling M, Alvfors C, Ringbom M, Nordström E, Söderlind K, Gullbo J. Berglund Å, et al. Among authors: ullen a. Invest New Drugs. 2015 Dec;33(6):1232-41. doi: 10.1007/s10637-015-0299-2. Epub 2015 Nov 10. Invest New Drugs. 2015. PMID: 26553306 Clinical Trial.
Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer.
Sarhan D, Leijonhufvud C, Murray S, Witt K, Seitz C, Wallerius M, Xie H, Ullén A, Harmenberg U, Lidbrink E, Rolny C, Andersson J, Lundqvist A. Sarhan D, et al. Among authors: ullen a. Oncoimmunology. 2017 Jun 14;6(8):e1338238. doi: 10.1080/2162402X.2017.1338238. eCollection 2017. Oncoimmunology. 2017. PMID: 28920001 Free PMC article.
99 results